Hannah J Lomax-Browne
Overview
Explore the profile of Hannah J Lomax-Browne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Visconti A, Rossi N, Bondt A, Ederveen A, Thareja G, Koeleman C, et al.
Genome Med
. 2024 Aug;
16(1):96.
PMID: 39123268
Background: Immunoglobulin (Ig) glycosylation modulates the immune response and plays a critical role in ageing and diseases. Studies have mainly focused on IgG glycosylation, and little is known about the...
2.
Lomax-Browne H, Medjeral-Thomas N, Barbour S, Gisby J, Han H, Bomback A, et al.
Clin J Am Soc Nephrol
. 2022 Jul;
17(7):994-1007.
PMID: 35777834
Background And Objectives: C3 glomerulopathy and idiopathic Ig-associated membranoproliferative GN are kidney diseases characterized by abnormal glomerular complement C3 deposition. These conditions are heterogeneous in outcome, but approximately 50% of...
3.
Dotz V, Visconti A, Lomax-Browne H, Clerc F, Hipgrave Ederveen A, Medjeral-Thomas N, et al.
J Am Soc Nephrol
. 2021 Jun;
32(10):2455-2465.
PMID: 34127537
Background: IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide and is a leading cause of renal failure. The disease mechanisms are not completely understood, but a higher...
4.
Malik T, Gitterman D, Lavin D, Lomax-Browne H, Hiemeyer E, Moran L, et al.
Proc Natl Acad Sci U S A
. 2021 Mar;
118(13).
PMID: 33753502
Genetic variation within the factor H-related (FHR) genes is associated with the complement-mediated kidney disease, C3 glomerulopathy (C3G). There is no definitive treatment for C3G, and a significant proportion of...
5.
Medjeral-Thomas N, Moffitt H, Lomax-Browne H, Constantinou N, Cairns T, Cook H, et al.
Kidney Int Rep
. 2019 Nov;
4(10):1387-1400.
PMID: 31701048
Introduction: Therapeutic agents that target complement are increasingly available for glomerular diseases. However, the mechanisms linking glomerular complement deposition with inflammation and damage are incompletely understood. Complement factor H-related protein...
6.
Lomax-Browne H, Robertson C, Antonopoulos A, Leathem A, Haslam S, Dell A, et al.
Interface Focus
. 2019 Mar;
9(2):20180079.
PMID: 30842877
The lectin agglutinin (HPA) recognizes altered glycosylation in solid cancers and the identification of HPA binding partners in tumour tissue and serum is an important aim. Among the many HPA...
7.
Zhu L, Guo W, Shi S, Liu L, Lv J, Medjeral-Thomas N, et al.
Kidney Int
. 2018 May;
94(1):150-158.
PMID: 29759419
IgA nephropathy (IgAN) is a disease associated with activation of the complement system. But the factors influencing complement activation in IgAN are not fully understood. Complement factor H (FH) is...
8.
Medjeral-Thomas N, Troldborg A, Constantinou N, Lomax-Browne H, Hansen A, Willicombe M, et al.
Kidney Int Rep
. 2018 May;
3(2):426-438.
PMID: 29725647
Introduction: IgA nephropathy (IgAN) is characterized by glomerular deposition of galactose-deficient IgA1 and complement proteins and leads to renal impairment. Complement deposition through the alternative and lectin activation pathways is...
9.
Medjeral-Thomas N, Lomax-Browne H, Beckwith H, Willicombe M, McLean A, Brookes P, et al.
Kidney Int
. 2017 Jul;
92(4):942-952.
PMID: 28673452
IgA nephropathy (IgAN) is a common cause of chronic kidney disease and end-stage renal failure, especially in young people. Due to a wide range of clinical outcomes and difficulty in...
10.
Lomax-Browne H, Visconti A, Pusey C, Cook H, Spector T, Pickering M, et al.
J Am Soc Nephrol
. 2016 Jun;
28(1):64-68.
PMID: 27313232
IgA nephropathy (IgAN) is the most common form of primary GN and an important cause of kidney failure. Characteristically, patients with IgAN have increased serum levels of undergalactosylated IgA1 (gd-IgA1)....